MIGRAINE, CAROTID STIFFNESS AND GENETIC POLYMORPHISM
Acta Clinica Croatica
|March 29, 2016
Summary
Migraine patients exhibit increased arterial stiffness and higher rates of procoagulant gene mutations compared to controls. These findings suggest a need for proactive monitoring to prevent stroke in individuals with migraine, especially those with white matter lesions.
Area of Science:
- Vascular Medicine
- Neurology
- Genetics
Background:
- Migraine is increasingly linked to vascular issues like arterial stiffness, stroke, and white matter lesions (WML).
- Understanding the vascular profile of migraineurs is crucial for stroke risk assessment.
Purpose of the Study:
- To compare functional carotid ultrasound parameters between migraine patients and headache-free controls.
- To investigate the prevalence of procoagulant gene mutations in migraineurs.
Main Methods:
- Carotid ultrasound using E-tracking software on Alpha 10 platform.
- Comparison of vascular parameters (intima-media thickness, diameter, stiffness indices) between 60 migraineurs and 45 controls.
- Genetic analysis for MTHFR, PAI-1, and ACE gene mutations; brain imaging for WML.
Main Results:
- Migraine patients showed significantly worse carotid vascular parameters, including increased intima-media thickness and arterial stiffness.
- Higher incidence of homozygous procoagulant gene mutations (MTHFR, PAI-1, ACE I/D) observed in migraineurs.
- White matter lesions (WML) detected in 11 migraine patients, four with migraine with aura.
Conclusions:
- Migraine is associated with increased carotid stiffness and a higher frequency of procoagulant gene mutations.
- Prospective ultrasound monitoring is recommended for migraine patients, particularly those with WML.
- Early detection can facilitate timely and targeted preventive stroke management strategies.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
12.3K
05:40Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
Published on: July 29, 2021
10.1K
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
01:27Principles of Pharmacogenetics: Types of Genetic Variants
87
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
87
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
108
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
108
01:27Pharmacogenetics of Drug Metabolism: Overview
106
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
106
01:05Single Nucleotide Polymorphisms-SNPs
19.7K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.7K